Financial writer advises caution on Jyong Biotech Ltd. IPO due to high debt, legal issues, and FDA challenges. Click for my ...

During a panel discussion at this year’s Fierce JPM Week—which took place alongside the annual J.P. | This week on “The Top ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...

Aurion Biotech, Inc. plans $100M IPO for corneal disease treatments, limited competition, Phase 1/2 trials underway with ...

Metsera and Maze Therapeutics priced their Nasdaq IPOs, raising $275M and $140M respectively. Both companies backed by ARCH ...

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

Maze has two kidney disease drugs currently in the clinical, and the biotech was able raise $140 million in IPO cash to support those programs and more in its pipeline. Maze’s shares now trade ...

After a nearly $300 million IPO little more than a year ago, a young Peninsula biotech company will discontinue what had been ...

Metsera Inc. is seeking to raise $292 million in an initial public offering, joining a clutch of health-care firms set to make their debuts as public companies.

There were only 36 biotech IPOs last year, compared with 68 in 2015 and a record 85 in 2014 – and a rebound was expected in 2017. Are biotech IPOs back in fashion? | pharmaphorum Skip to main ...

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...